| scholarly article | Q13442814 |
| P2093 | author name string | Dominik Wolf | |
| Peter Brossart | |||
| Annkristin Heine | |||
| P2860 | cites work | A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma | Q24319940 |
| Cancer immunotherapy: moving beyond current vaccines | Q24548229 | ||
| Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer | Q24632187 | ||
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion | Q27860475 | ||
| Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Toll-like receptors | Q27860671 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells | Q39692679 | ||
| EpiToolKit--a web server for computational immunomics | Q39784947 | ||
| Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. | Q39822750 | ||
| Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. | Q40357536 | ||
| Chemistry of peptides associated with MHC class I and class II molecules | Q40540085 | ||
| Tumor antigens recognized by T lymphocytes | Q40661131 | ||
| Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells | Q40741896 | ||
| Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. | Q41857208 | ||
| A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients | Q42858412 | ||
| Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer | Q44133324 | ||
| Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells | Q44432115 | ||
| Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma | Q45054030 | ||
| Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. | Q45200866 | ||
| Lymphoproliferation in CTLA-4–Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4 + T Cells | Q46091258 | ||
| Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients | Q46093084 | ||
| Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy | Q46258212 | ||
| Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses | Q46725768 | ||
| Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients | Q48030305 | ||
| Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial | Q50966333 | ||
| Targeting oncogenic drivers and the immune system in melanoma | Q53128890 | ||
| Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses. | Q54321271 | ||
| Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival | Q56986695 | ||
| Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis | Q56986719 | ||
| T Cell Assays and MIATA: The Essential Minimum for Maximum Impact | Q58025436 | ||
| Vascular normalization in Rgs5-deficient tumours promotes immune destruction | Q58897988 | ||
| Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas | Q73937540 | ||
| Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity | Q80557815 | ||
| Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial | Q83427167 | ||
| Calreticulin exposure dictates the immunogenicity of cancer cell death | Q28280438 | ||
| Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice | Q29615615 | ||
| Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors | Q29615665 | ||
| The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis | Q29617049 | ||
| Immunosuppressive strategies that are mediated by tumor cells | Q29636247 | ||
| Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice | Q30481516 | ||
| Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). | Q33266751 | ||
| Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts | Q33730171 | ||
| Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases | Q33788932 | ||
| Effector memory T cells, early metastasis, and survival in colorectal cancer | Q33992461 | ||
| The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation | Q34015801 | ||
| Strategies to use immune modulators in therapeutic vaccines against cancer | Q34275601 | ||
| Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer | Q34543188 | ||
| Tregs and rethinking cancer immunotherapy | Q34625147 | ||
| Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients | Q34994511 | ||
| Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. | Q35382105 | ||
| Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? | Q35594089 | ||
| A listing of human tumor antigens recognized by T cells: March 2004 update | Q35862179 | ||
| Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy | Q36378276 | ||
| Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment | Q36944380 | ||
| NLRs at the intersection of cell death and immunity | Q37117573 | ||
| Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines | Q37140636 | ||
| Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement | Q37193049 | ||
| Immune therapy for cancer | Q37324793 | ||
| Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines | Q37424192 | ||
| Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. | Q37435472 | ||
| Dendritic cell vaccination as a treatment modality for melanoma | Q37628701 | ||
| Basic science for the clinician 55: CTLA-4. | Q37997916 | ||
| Cellular constituents of immune escape within the tumor microenvironment | Q38020632 | ||
| Cross-presentation by dendritic cells | Q38025870 | ||
| BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. | Q39212469 | ||
| VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer | Q39252038 | ||
| T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment | Q39300005 | ||
| Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice | Q39400640 | ||
| P433 | issue | 1 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | e27588 | |
| P577 | publication date | 2014-01-03 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning | |
| P478 | volume | 3 |
| Q39387761 | A Primer for Oncoimmunology (Immunooncology). |
| Q35886393 | Adding fuel to the fire: immunogenic intensification |
| Q45878573 | Antithymidylate resistance enables transgene selection and cell survival for T cells in the presence of 5-fluorouracil and antifolates |
| Q37012691 | Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy |
| Q35886454 | Regulatory considerations for clinical development of cancer vaccines |
| Q41936234 | The anticancer functions of RIG-I-like receptors, RIG-I and MDA5, and their applications in cancer therapy |
| Q38866734 | Tumor suppressor activity of RIG-I. |
| Q41010318 | Tumor vaccines and peptide-loaded dendritic cells (DCs) |
Search more.